Donlon NE, Elliott JA, Donohoe CL, Murphy CF, Nugent T, Moran B, King S, Ravi N, Reynolds JV. Adverse biology in adenocarcinoma of the esophagus and esophagogastric junction impacts survival and response to neoadjuvant therapy independent of anatomic subtype. Ann Surg. 2020;272(5):814–9.

Article  PubMed  Google Scholar 

Chevallay M, Bollschweiler E, Chandramohan SM, Schmidt T, Koch O, Demanzoni G, Monig S, Allum W. Cancer of the gastroesophageal junction: a diagnosis, classification, and management review. Ann N Y Acad Sci. 2018;1434(1):132–8.

Article  PubMed  Google Scholar 

Sakaue S, Kanai M, Tanigawa Y, Karjalainen J, Kurki M, Koshiba S, Narita A, Konuma T, Yamamoto K, Akiyama M, et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nat Genet. 2021;53(10):1415–24.

Article  CAS  PubMed  Google Scholar 

Rubenstein JH, Shaheen NJ. Epidemiology, diagnosis, and management of esophageal adenocarcinoma. Gastroenterology. 2015;149(2):302-317.e1.

Article  PubMed  Google Scholar 

Shakeri R, Malekzadeh R, Etemadi A, Nasrollahzadeh D, Aghcheli K, Sotoudeh M, Islami F, Pourshams A, Pawlita M, Boffetta P, et al. Opium: an emerging risk factor for gastric adenocarcinoma. Int J Cancer. 2013;133(2):455–61.

Article  CAS  PubMed  Google Scholar 

Liu X, Jiang Q, Yue C, Wang Q. Clinicopathological characteristics and survival predictions for adenocarcinoma of the esophagogastric junction: a SEER population-based retrospective study. Int J Gen Med. 2021;14:10303–14.

Article  PubMed  PubMed Central  Google Scholar 

Nakauchi M, Vos EL, Carr RA, Barbetta A, Tang LH, Gonen M, Russo A, Janjigian YY, Yoon SS, Sihag S, et al. Distinct differences in gastroesophageal junction and gastric adenocarcinoma in 2194 patients. Ann Surg. 2023;277(4):629–36.

Article  PubMed  Google Scholar 

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.

Article  CAS  PubMed  Google Scholar 

Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4(5): e180013.

Article  PubMed  PubMed Central  Google Scholar 

Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419–30.

Article  CAS  PubMed  Google Scholar 

Almhanna K, Kalebic T, Cruz C, Faris JE, Ryan DP, Jung J, Wyant T, Fasanmade AA, Messersmith W, Rodon J. Phase I study of the investigational anti-guanylyl cyclase antibody-drug conjugate TAK-264 (MLN0264) in adult patients with advanced gastrointestinal malignancies. Clin Cancer Res. 2016;22(20):5049–57.

Article  CAS  PubMed  Google Scholar 

Bardia A, Messersmith WA, Kio EA, Berlin JD, Vahdat L, Masters GA, Moroose R, Santin AD, Kalinsky K, Picozzi V, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Ann Oncol. 2021;32(6):746–56.

Article  CAS  PubMed  Google Scholar 

Capone E, Lattanzio R, Gasparri F, Orsini P, Rossi C, Iacobelli V, De Laurenzi V, Natali PG, Valsasina B, Iacobelli S, et al. EV20/NMS-P945, a novel thienoindole based antibody-drug conjugate targeting HER-3 for solid tumors. Pharmaceutics. 2021;13(4):483.

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Brien NA, McDermott MSJ, Zhang J, Gong KW, Lu M, Hoffstrom B, Luo T, Ayala R, Chau K, Liang M, et al. Development of a novel CLDN18.2-directed monoclonal antibody and antibody-drug conjugate for treatment of CLDN18.2-positive cancers. Mol Cancer Ther. 2023;22(12):1365–75.

Article  PubMed  Google Scholar 

Li S, Yuan L, Xu ZY, Xu JL, Chen GP, Guan X, Pan GZ, Hu C, Dong J, Du YA, et al. Integrative proteomic characterization of adenocarcinoma of esophagogastric junction. Nat Commun. 2023;14(1):778.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lumish MA, Walch H, Maron SB, Chatila W, Kemel Y, Maio A, Ku GY, Ilson DH, Won E, Li J, et al. Clinical and molecular characteristics of early-onset vs. average-onset esophagogastric cancer. J Natl Cancer Inst. 2024;116(2):299–308.

Article  CAS  PubMed  Google Scholar 

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4.

Article  PubMed  Google Scholar 

Nakauchi M, Walch HS, Nussenzweig S, Carr R, Vos E, Berger MF, Schultz N, Janjigian Y, Wu A, Tang L, et al. Genomic landscape of adenocarcinomas across the gastroesophageal junction: moving on from the Siewert classification. Ann Surg. 2024;10.1097/SLA.0000000000006363.

Janjigian YY, Sanchez-Vega F, Jonsson P, Chatila WK, Hechtman JF, Ku GY, Riches JC, Tuvy Y, Kundra R, Bouvier N, et al. Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer Discov. 2018;8(1):49–58.

Article  CAS  PubMed  Google Scholar 

Camps J, Noel F, Liechti R, Massenet-Regad L, Rigade S, Gotz L, Hoffmann C, Amblard E, Saichi M, Ibrahim MM, et al. Meta-analysis of human cancer single-cell RNA-seq datasets using the IMMUcan database. Cancer Res. 2023;83(3):363–73.

Article  CAS  PubMed  Google Scholar 

Zhang P, Yang M, Zhang Y, Xiao S, Lai X, Tan A, Du S, Li S. Dissecting the single-cell transcriptome network underlying gastric premalignant lesions and early gastric cancer. Cell Rep. 2019;27(6):1934-1947.e5.

Article  CAS  PubMed  Google Scholar 

Zhang P, Tao C, Shimura T, Huang AC, Kong N, Dai Y, Yao S, Xi Y, Wang X, Fang J, et al. ICAM1 antibody drug conjugates exert potent antitumor activity in papillary and anaplastic thyroid carcinoma. iScience. 2023;26(8): 107272.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guo P, Huang J, Zhu B, Huang AC, Jiang L, Fang J, Moses MA. A rationally designed ICAM1 antibody drug conjugate eradicates late-stage and refractory triple-negative breast tumors in vivo. Sci Adv. 2023;9(18):eabq7866.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol. 2012;30(7):631–7.

Article  CAS  PubMed  Google Scholar 

Liao-Chan S, Daine-Matsuoka B, Heald N, Wong T, Lin T, Cai AG, Lai M, D’Alessio JA, Theunissen JW. Quantitative assessment of antibody internalization with novel monoclonal antibodies against Alexa fluorophores. PLoS ONE. 2015;10(4): e0124708.

Article  PubMed  PubMed Central  Google Scholar 

Pinkert J, Boehm HH, Trautwein M, Doecke WD, Wessel F, Ge Y, Gutierrez EM, Carretero R, Freiberg C, Gritzan U, et al. T cell-mediated elimination of cancer cells by blocking CEACAM6-CEACAM1 interaction. Oncoimmunology. 2022;11(1):2008110.

Article  PubMed  Google Scholar 

Nakada T, Masuda T, Naito H, Yoshida M, Ashida S, Morita K, Miyazaki H, Kasuya Y, Ogitani Y, Yamaguchi J, et al. Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads. Bioorg Med Chem Lett. 2016;26(6):1542–5.

Article  CAS  PubMed  Google Scholar 

Huang J, Agoston AT, Guo P, Moses MA. A Rationally designed ICAM1 antibody drug conjugate for pancreatic cancer. Adv Sci. 2020;7(24):2002852.

Article  CAS  Google Scholar 

Abedi M, Ahangari Cohan R, Mahboudi F, Shafiee Ardestani M, Davami F. MALDI-MS: a rapid and reliable method for drug-to-antibody ratio determination of antibody-drug conjugates. Iran Biomed J. 2019;23(6):395–403.

Article  PubMed